Project description
A combined approach to identifying potential biomarkers for autism spectrum disorders
Autism spectrum disorders (ASD) affect around 1 in 54 children and can cause significant social, communication and behavioural challenges. Currently, there are no proven ASD biomarkers; diagnosis relies entirely on behavioural evaluations. The EU-funded GEMMA project plans to combine for the first time multi-omics with environmental data for analysing the composition and function of the microbiome for personalised treatment, and ultimately, disease interception in at-risk infants. The goal is to provide solid insight into ASD onset and its progression in relation to dynamic changes in abnormal gut microbiota and develop targets for possible treatment and prevention. Observations of these epigenetic modifications that control gut barrier and immune functions will be based on in-depth evaluation of 600 infants at risk observed from birth and thereafter.
Fields of science
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
Participants (15)
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
SW7 2AZ London